BGI Genomics Co Ltd
300676
Company Profile
Business description
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Contact
21 Hongan Third Street
Dong
Huada Complex Park
Yantian District
Shenzhen518083
CHNT: +86 75536307065
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
3,702
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
This company dominates its industry and could be flirting with regulatory intervention.
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,088.70 | 22.40 | -0.25% |
| CAC 40 | 7,635.03 | 13.99 | 0.18% |
| DAX 40 | 23,924.36 | 78.29 | 0.33% |
| Dow JONES (US) | 44,193.12 | 81.38 | 0.18% |
| FTSE 100 | 9,164.31 | 21.58 | 0.24% |
| HKSE | 25,018.97 | 108.34 | 0.43% |
| NASDAQ | 21,169.42 | 252.87 | 1.21% |
| Nikkei 225 | 41,081.22 | 286.36 | 0.70% |
| NZX 50 Index | 12,922.20 | 42.04 | 0.33% |
| S&P 500 | 6,345.06 | 45.87 | 0.73% |
| S&P/ASX 200 | 8,819.20 | 24.50 | -0.28% |
| SSE Composite Index | 3,638.40 | 4.40 | 0.12% |